Breaking News, Collaborations & Alliances

Celonic, LINDIS Biotech Sign Manufacturing Agreement for Catumaxomab

Celonic will produce catumaxomab at its manufacturing facility in Heidelberg, Germany.

Author Image

By: Charlie Sternberg

Associate Editor

Samanta Cimitan, CEO Celonic Group, Horst Lindhofer, CEO LINDIS Biotech.

Celonic Group, a biologics CDMO, has signed a multi-year commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab for Commercial Supply. Catumaxomab, a trifunctional bispecific monoclonal antibody, is specifically designed for the intraperitoneal treatment of malignant ascites in adult patients with epithelial cell adhesion molecule (EpCAM)-positive carcinomas. This treatment option is particularly valuable for those who are ineligible for conventional systemic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters